The Role of Genetic Factors in the Development of Epilepsy in the Kazakh Population

Epilepsy Clinical Trial

Official title:

Preventive and Personalized Medicine (2021-2023)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05088499
• Other study ID #: 1199
• Status: Completed
• Start date: February 1, 2022
• Est. completion date: January 20, 2023

Study information

• Verified date: March 2023
• Source: Asfendiyarov Kazakh National Medical University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

This is a GWAS study that aims to identify possible candidate genes associate to epilepsy by exploring single nucleotide polymorphism (SNP) in a group of epilepsy, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associate with epilepsy

Description:

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies

Recruitment information / eligibility

• Status: Completed
• Enrollment: 600
• Est. completion date: January 20, 2023
• Est. primary completion date: January 20, 2023
• Gender: All
• Age group: 0 Years to 5 Years

Eligibility

Inclusion Criteria:

• Children with seizures, confirmed by EEG and no morphological damage to the brain, confirmed by MRI of the brain;

• The age of the patients is from 0 to 5 years;

• Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs;

• Children are parents or legal guardians who have given written informed consent.

Exclusion Criteria:

• Children over 5 years old;

• Children whose parents, according to the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;

• Children with seizures with brain damage that cause epilepsy;

• Children of a non-Kazakh ethnic group.

Related Conditions & MeSH terms

• Epilepsy

Intervention

Genetic:
• DNA analysis
GWAS

Locations

Country	Name	City	State
Kazakhstan	Altynshash Jaxybayeva	Almaty

Sponsors (1)

Lead Sponsor	Collaborator
Asfendiyarov Kazakh National Medical University

Country where clinical trial is conducted

Kazakhstan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	number of SNPs associated with epilepsy	Using GWAS to identify candidate genes associate with epilepsy	1 year